Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2458324 | 0.87 | JAK2 (0.77) | JAK2KCNH2 | |
| SCHEMBL2455567 | 0.87 | JAK2 (0.77) | JAK2KCNH2 | |
| SCHEMBL2457901 | 0.87 | JAK2 (0.77) | JAK2KCNH2 | |
| SCHEMBL2456507 | 0.87 | JAK2 (1.00) | JAK2KCNH2 | |
| SCHEMBL2457935 | 0.87 | JAK2 (0.77) | JAK2KCNH2 | |
| SCHEMBL2455997 | 0.85 | JAK2 (0.73) | JAK2KCNH2 | |
| SCHEMBL2457968 | 0.84 | JAK2 (0.72) | JAK2KCNH2 | |
| SCHEMBL2455316 | 0.84 | JAK2 (0.72) | JAK2KCNH2 | |
| SCHEMBL13296815 | 0.84 | JAK2 (0.72) | JAK2KCNH2 | |
| SCHEMBL2457931 | 0.82 | JAK2 (0.70) | JAK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329722-B2 | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329722-B2 | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8329722-B2 | Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1 | MERCK SHARP & DOHME CORP. (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2134346-B1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME (US) | 2011-09-21 | — | — | EP | disclosed |
| EP-2134346-B1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20100160309-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160309-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| US-20100160309-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK SHARP & DOHME LLC | 2010-06-24 | — | — | US | disclosed |
| EP-2134346-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | Merck & Co., Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112217-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112217-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160309-A1 | INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1 | JAK2, PDK1, JAK1 | JAK2 1/4885KCNH2 2002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.